Arecor patents heat stable adenovirus vaccine technology

Angela Buckler, manager of Arecor's virology formulation group, describes their exciting new patent application for adenovirus formulation. It enables cancer therapies and vaccines, such as HIV, to be stored at ambient temperatures of 2-8C instead of -80C which was previously required. This ground breaking technology retains the potency of life saving therapies and enables them to reach medical centres in remote parts of the world where sub-zero storage facilities were not available. For further information, see http://www.arecor.com/news-events/arecor-patents-ground-breaking-heat-stable/